Bispecific antibodies, targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF), showed TAMs reprogramming and delayed tumor growth in glioma murine models [149]. The gene discussed is VEGFA; the disease is central nervous system cancer.